HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Core Insights - HCW Biologics congratulates Wugen on its $115 million equity financing led by Fidelity Management & Research Company, indicating strong institutional support for Wugen's development of CAR-T cell therapies [1][3] - HCW Biologics holds a minority equity interest in Wugen, which has generated $16.2 million in revenue from a license agreement since its inception [2] Company Overview: HCW Biologics - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing immunotherapies targeting chronic inflammation and age-related diseases [3] - The company’s lead product candidate, HCW9302, is developed using the TOBI™ platform, and it has also created the TRBC platform for constructing various immunotherapeutics [3] - HCW Biologics has over 50 molecules in development using the TRBC platform, with ongoing preclinical evaluations [3] Company Overview: Wugen - Wugen is a pivotal-stage biotechnology company specializing in off-the-shelf cell therapies derived from healthy donor cells, aimed at treating hematologic malignancies [4] - The company utilizes a proprietary CAR-T platform to address unmet medical needs and has optimized its US-based manufacturing for scalability and rapid deployment [4]